NCT06441123 Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein
| NCT ID | NCT06441123 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | HIV Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-02-10 |
| Primary Completion | 2027-02-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 24 participants in total. It began in 2025-02-10 with a primary completion date of 2027-02-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV. One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the "shock-and-kill" strategy, involves waking up the hidden virus ("shock" phase) so that it can be destroyed by the body's immune system or by the virus itself ("kill" phase). Investigators are developing new LRAs that target and activate a viral protein called Tat, which is necessary for the virus to start producing again and for reversing its dormant state.The lead compound, named D10, is the first of its kind to target the Tat protein. This compound has been patented and has shown activity in activating the virus in lab-grown cells. Now, investigators need to test its effectiveness on real target cells from people living with HIV.
Eligibility Criteria
Inclusion Criteria: * Patient aged 18 years or older * HIV-positive * On ART (antiretroviral therapy) * HIV-1 RNA undetectable for more than 12 months * Nadir CD4 count \< 200/µL Exclusion Criteria: * Lack of antiretroviral treatment * Immunosuppressive treatments * History of cancer less than 5 years old * Pregnant or breast-feeding women * Persons protected by law (under guardianship or curators), persons under court protection * Participating in another research project with an ongoing exclusion period * Refusal to participate in research * Subject not affiliated to a social security scheme, or not benefiting from such a scheme.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06441123 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06441123 currently recruiting?
Yes, NCT06441123 is actively recruiting participants. Contact the research team at a-makinson@chu-montpellier.fr for enrollment information.
Where is the NCT06441123 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT06441123 clinical trial?
NCT06441123 is sponsored by University Hospital, Montpellier. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.